Abstract:Abstract Background: Genetic testing for patients with breast cancer (BCa) patients may change the routine patient care and shift the paradigm towards more personalized managing and treatment strategies. In particular, testing germline mutations in BRCA1/2 has become a part of the standard clinical practice for patients with BCa. However, our understanding of genetic epidemiology of BCa is mainly driven by data from Caucasian populations and it has been evident that gene alterations may be ethnic specific in breast cancer. Methods: Aiming to delineate the landscape of germline mutations in Chinese patients with BCa to breast cancer, we collected blood samples from in 356 BCa patients at stage I-IV in Beijing Cancer Hospital between Jan. 2013 to Dec. 2019. Peripheral blood mononuclear cells were isolated from blood samples and genomic DNA were extracted for capture-based NGS sequencing. A large comprehensive 600 gene panel (PredicineATLAS, Huidu Medical Science Techonology, Inc.) was used to detect germline mutations in the covered genes with average 300x sequencing depth. Results: A total of 356 BCa patients were included in our study, with the median age at first diagnosis of 49 years (Range: 21-87). Among all cases, 21.9% (78/356, 95% confidence interval [CI]: 17.7-26.6%) carried pathogenic or likely pathogenic mutations in 48 cancer related genes. Twenty-seven patients (7.6%, 95% CI: 5.1-10.8%) harbored BRCA1/2 mutations, followed by 5 patients carrying ATM mutations and RAD50 mutations respectively. Other commonly mutated genes include BARD1 (1.1%), FANCD2 (1.1%), CHEK2 (0.6%), FANCC (0.6%), FANCM (0.6%), PMS2 (0.6%), and TP53 (0.6%), most of which are related to DNA damage repair pathway. Moreover, BRCA1/2 carriers were more likely to appear among those with breast or ovarian cancer family history than those without (OR=3.41, 95% CI: 1.14-9.12, P=0.01). Compared with patients that aged older than 50 years at first diagnosis, those aged 30 years or younger were 6 times more likely to detect germline mutations in BRCA1/2 (95% CI: 1.18-26.1, P=0.02). In addition, mutations in BRCA1/2 were differentially associated with breast cancer subtypes. BRCA1 mutations were strongly enriched in triple-negative breast cancer (TNBC) (OR=6.7, 95% CI: 1.54-33.13, P=0.005). There is no strong significant survival difference observed between BRCA1/2 carriers and non-carriers, however, patients carrying ATM or RAD50 mutations tend to have lower disease-free survival. Conclusions: This is a comprehensive analysis of germline mutation spectrum in a large Chinese patient cohort with breast cancer. Collectively, a substantial proportion of patients with breast cancer had hereditary risk factors. Distinct distribution of pathogenic mutations in breast cancer subtypes and differential associations between mutation status and clinical features were further observed. All these findings will advance our understanding regarding the pathologies and heterogeneity of breast cancer. Citation Format: Nan Wang, Jiayang Zhang, Lu Tan, Hao Liao, Yaxin Liu, Xinyu Gui, Jiaxin Niu, Feng Xie, Yue Zhang, Yong Huang, Jianjun Yu, Huiping Li. Germline mutation landscape in Chinese breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS16-08.

Prevalence and Clinical Significance of Pathogenic Germline BRCA1/2 Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Pathogenic Germline Mutation Profile In Chinese Lung Cancers And Related-Driver Mutation Pattern.

Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.

Mutations and Expressions of Breast Cancer 1/2 in Lung Cancer

Pathogenic germline variants in BRCA1 and TP53 increase lung cancer risk in Chinese

BRCA1/2 Germline Mutations and Response to PARP Inhibitor Treatment in Lung Cancer.

Germline and Tumor BRCA1/2 Mutations in Chinese High Grade Serous Ovarian Cancer Patients.

Prevalence Of Brca1 And Brca2 Gene Mutations In Chinese Patients With High-Risk Breast Cancer

Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing

BRCA1/2 Mutation Spectrum in Chinese Early-Onset Breast Cancer

Germline Mutations in 40 Cancer Susceptibility Genes among Chinese Patients with High Hereditary Risk Breast Cancer

Genomic features of lung cancer patients harboring germline mutations associated with hereditary cancer syndromes.

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Prevalence And Clinical Outcomes Of Germline Mutations In Brca1/2 And Palb2 Genes In 2769 Unselected Breast Cancer Patients In China

The Co-Mutation of EGFR and Tumor-Related Genes Leads to a Worse Prognosis and a Higher Level of Tumor Mutational Burden in Chinese Non-Small Cell Lung Cancer Patients